A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies (PRESERVEI) (Transplant)
Bone Marrow Transplant (BMT) Study in Patients with Acute Leukemia
Sponsor: Ossium Health
Enrolling: Male and Female Patients
IRB Number: AAAU5840
U.S. Govt. ID: NCT05589896
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to learn if a transplant using bone marrow recovered from deceased organ and tissue donors is safe and effective in patients undergoing bone marrow transplant (BMT). This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard of care for transplant. Bone marrow cells from a deceased organ and tissue donor in your transplant is the investigational treatment in this study and has not yet been approved by the Food and Drug Administration (FDA). This study is the first in human study that will use deceased donor bone marrow for the treatment of hematological malignancies.
Markus Mapara, MD
Do You Qualify?
Are you between the ages of 18-70? Yes No
Have you been diagnosed with acute leukemia? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator